Table 1.
Demographic data of study groups
| Control | Drug-med pts | Drug-free | Drug-naïve | |||
| (N=31) | (N=44) | pts(N=28) | pts(N=15) | p-value** | ||
| Age* | 33.9 ± 9.5 | 37.3 ± 11.4 | 35.1 ± 9.1 | 30.8 ± 7.7 | NS*** | |
| Sex | Male | 17 | 33 | 6 | 16 | NS*** |
| Female | 14 | 11 | 9 | 15 | ||
| Age of symptom onset* | 22.5 ± 6.8 | 26.7 ± 9.2 | 28.1 ± 7.8 | NS*** | ||
| Duration of illness* | 12.7 ± 8.3 | 7.6 ± 5.2 | 2.5 ± 3.0 | <0.01 | ||
| TBPRS | 36.1 ± 12.9 | 41.9 ± 25.4 | 36.9 ± 18.2 | NS*** | ||
| Dose of antipsychotics**** | 1000.1 ± 130.4 | 769.6 ± 491.2 | 614.2 ± 234.7 | NS*** | ||
| Duration of no-medication | 10.61 ± 7.01 | |||||
| (mean months ± SD) | ||||||
* :mean ± standard deviation (years) ** :one-way ANOVA test, independent T-test, Chi-square test *** :NS; statistically non-significant **** :chlorpromazine equivalent dose (mg/cay)